Head to Head Contrast: Xenetic Biosciences (XBIO) vs. The Competition

Xenetic Biosciences (NASDAQ:XBIO – Get Free Report) is one of 843 publicly-traded companies in the “Biotechnology” industry, but how does it compare to its rivals? We will compare Xenetic Biosciences to related companies based on the strength of its valuation, earnings, dividends, profitability, institutional ownership, risk and analyst recommendations.

Profitability

This table compares Xenetic Biosciences and its rivals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Xenetic Biosciences -123.72% -53.79% -47.26%
Xenetic Biosciences Competitors -12,319.70% -407.93% -30.95%

Valuation and Earnings

This table compares Xenetic Biosciences and its rivals gross revenue, earnings per share and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Xenetic Biosciences $2.98 million -$2.68 million -0.96
Xenetic Biosciences Competitors $715.39 million $10.31 million -18.32

Xenetic Biosciences’ rivals have higher revenue and earnings than Xenetic Biosciences. Xenetic Biosciences is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.

Insider & Institutional Ownership

15.1% of Xenetic Biosciences shares are owned by institutional investors. Comparatively, 47.8% of shares of all “Biotechnology” companies are owned by institutional investors. 7.6% of Xenetic Biosciences shares are owned by insiders. Comparatively, 13.1% of shares of all “Biotechnology” companies are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Analyst Recommendations

This is a summary of current ratings for Xenetic Biosciences and its rivals, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Xenetic Biosciences 1 0 0 0 1.00
Xenetic Biosciences Competitors 9931 15323 45708 1605 2.54

As a group, “Biotechnology” companies have a potential upside of 131.56%. Given Xenetic Biosciences’ rivals stronger consensus rating and higher possible upside, analysts clearly believe Xenetic Biosciences has less favorable growth aspects than its rivals.

Volatility & Risk

Xenetic Biosciences has a beta of 2.36, suggesting that its share price is 136% more volatile than the S&P 500. Comparatively, Xenetic Biosciences’ rivals have a beta of -1.84, suggesting that their average share price is 284% less volatile than the S&P 500.

Summary

Xenetic Biosciences rivals beat Xenetic Biosciences on 9 of the 12 factors compared.

About Xenetic Biosciences

(Get Free Report)

Xenetic Biosciences, Inc. is a biotechnology company focused on developing immuno-oncology treatments. Its XCART platform is designed to create personalized CAR T-cell therapies that recognize tumor-specific antigens on B-cell lymphomas, with the goal of targeting cancer cells while limiting effects on healthy cells. The company’s earlier work included PolyXen, a drug-delivery platform based on polysialic acid that was designed to extend the time biologic medicines remain in the body. Xenetic’s current stated focus is advancing its XCART technology and related product candidates.

Receive News & Ratings for Xenetic Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xenetic Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.